1. Why Cholesterol Guidance Is in the News Again
Over the past twelve months, cardiology has produced an unusually dense run of lipid-related publications. A new US dyslipidemia guideline replaced the 2018 cholesterol guideline, a large outcomes trial of a PCSK9 antibody in patients with no prior heart attack or stroke was published, and the European Society of Cardiology Congress 2026 added further data on early LDL-cholesterol lowering. This article summarises what those sources report, so that hospital pharmacists, cardiology departments and procurement teams can follow the discussion.
A.K. Pharma, a medicine distributor in Delhi and pharmaceutical distributor in Delhi, supplies PCSK9-pathway medicines to healthcare institutions across India. We are not clinicians; we do not advise on who should receive any therapy. What follows is reporting on published evidence, with the original sources linked throughout.
1.1 Timeline of the Key Publications
| Date | Event | Source |
|---|---|---|
| Aug 2025 | US FDA expanded the evolocumab label to include high-risk adults without established cardiovascular disease (as reported by TCTMD) | TCTMD |
| Nov 2025 | VESALIUS-CV presented at AHA 2025 and published in the New England Journal of Medicine | NEJM / TCTMD |
| 13 Mar 2026 | 2026 ACC/AHA Dyslipidemia Guideline published, replacing the 2018 blood cholesterol guideline | JACC / Circulation |
| Mar 2026 | VESALIUS-CV diabetes subgroup analysis presented at ACC.26 and published in JAMA | ACC / JAMA |
| Late Aug 2026 | ESC Congress 2026 (Munich) — AMUNDSEN, BRIDGE and additional lipid data presented | ACC Cardiology magazine |
| 1 Oct 2026 | ACC Cardiology magazine publishes its ESC Congress 2026 recap | ACC |
Framing note: these are landmark 2025–2026 publications, not breaking news. Dates are as reported by the cited sources.
2. The 2026 ACC/AHA Dyslipidemia Guideline at a Glance
The 2026 ACC/AHA Guideline on the Management of Dyslipidemia (also published in JACC) retires and replaces the 2018 AHA/ACC blood cholesterol guideline. According to the ACC’s summary of the guideline, it is intended as a “one-stop shop” covering evaluation, management and monitoring of high cholesterol, hypertriglyceridemia and elevated lipoprotein(a).
2.1 What the Guideline States on Treatment Goals
The ACC summary reports that LDL-C and non-HDL-C treatment goals have returned to guide therapy. The goals stated in the guideline are:
| Risk group (as described in the guideline) | LDL-C goal stated | Non-HDL-C goal stated |
|---|---|---|
| Borderline or intermediate risk | < 100 mg/dL (2.6 mmol/L) | < 130 mg/dL (3.4 mmol/L) |
| High risk | < 70 mg/dL (1.8 mmol/L) | < 100 mg/dL (2.4 mmol/L) |
| Very-high-risk clinical ASCVD (secondary prevention) | < 55 mg/dL (1.4 mmol/L) | < 85 mg/dL (2.2 mmol/L) |
Whether any goal applies to a given patient, and how to reach it, is a determination for the treating physician.
2.2 Risk Assessment Changes Reported
- The guideline recommends the newer PREVENT-ASCVD equations in place of the older Pooled Cohort Equations for 10- and 30-year risk estimation in adults aged 30–79 years.
- Selective use of coronary artery calcium (CAC) scoring is described for men over 40 and women over 45 with borderline or intermediate risk.
- Lipoprotein(a) is to be measured at least once in adulthood, according to the ACC summary.
- Apolipoprotein B (apoB) may be used to assess residual risk in people with type 2 diabetes, high triglycerides, cardiovascular-kidney-metabolic syndrome or known cardiovascular disease.
2.3 Special Populations Mentioned
The guideline summary references tailored considerations for people with diabetes, chronic kidney disease, and familial hypercholesterolemia, and discusses the age at which treatment needs apply in younger, lower-risk people.
3. What the Guideline Says About Non-Statin Therapy
3.1 PCSK9 Monoclonal Antibodies
The guideline summary describes PCSK9 monoclonal antibodies — evolocumab (Repatha) and alirocumab (Praluent) — as an option for patients who do not reach LDL-C goals on maximally tolerated statin therapy, consistent with their approved indications.
3.2 Inclisiran
Inclisiran (marketed by A.K. Pharma as Sybrava), a small interfering RNA therapy dosed twice yearly after initial doses, is described as another non-statin option for LDL-C lowering in the same treatment pathway.
3.3 Evidence Note
Cardiovascular outcomes trial data for the PCSK9 antibodies (FOURIER for evolocumab, ODYSSEY Outcomes for alirocumab) have been published for several years. For inclisiran, the dedicated cardiovascular outcomes trials (ORION-4 and VICTORION-2P) are still in progress; the inclisiran label and current guideline text describe LDL-C lowering, not yet a completed outcomes trial read-out.
4. VESALIUS-CV — The Trial Behind Much of the Discussion
4.1 Design and Population
- VESALIUS-CV tested evolocumab in patients with elevated LDL-C but no prior heart attack or stroke — a primary-prevention population, broader than most earlier PCSK9 antibody trials.
- Presented at AHA 2025 and published in the New England Journal of Medicine.
4.2 Key Results Reported
| Measure | Result reported |
|---|---|
| LDL-C lowering reported in the 2026 guideline | 45%–84% (class range for PCSK9 antibodies) |
| Cardiovascular outcomes trial evidence (as cited) | FOURIER (NEJM 2017); VESALIUS-CV (NEJM 2025); ODYSSEY Outcomes (NEJM 2018) |
| Where it is named in the 2026 guideline | As a PCSK9 antibody add-on option |
4.3 Diabetes Subgroup Reported at ACC.26
A subgroup analysis of VESALIUS-CV in patients with diabetes was presented at ACC.26 and published in JAMA. An editorial accompanying that analysis raised open questions about cost-effectiveness and the age at which treatment should start; the diabetes subgroup reported was 93% White, a limitation the editorial also noted.
4.4 How the Guideline Authors Responded
In an editorial published alongside the guideline, its chair and vice-chair wrote that VESALIUS-CV results “have important implications” and should be addressed in future guideline updates, noting that the findings “blur the distinction between ASCVD risk categories when defining a goal LDL-C value.” In other words, the new guideline was completed before VESALIUS-CV fully entered the guidance, and its authors anticipated future revisions.
5. What Was Reported at ESC Congress 2026
The ACC’s October 2026 Cardiology magazine recap of ESC Congress 2026 lists several lipid-related presentations. AMUNDSEN and BRIDGE were among the studies reported there, alongside additional early LDL-cholesterol lowering data presented at the Munich meeting. We have not reviewed the full trial publications for these studies and report here only what the ACC recap states.
6. The Three PCSK9-Pathway Agents — A Descriptive Comparison
The table below summarises factual, label- and publication-level characteristics of the three PCSK9-pathway agents that A.K. Pharma distributes. It is a reference summary, not a ranking or a treatment recommendation. Dosing information reflects the manufacturers’ approved labelling as listed on our product pages; the treating physician determines dosing for any patient, and the approved Indian label should be consulted.
| Feature | Repatha (Evolocumab) | Praluent (Alirocumab) | Sybrava (Inclisiran) |
|---|---|---|---|
| Type | Human monoclonal antibody (anti-PCSK9) | Human monoclonal antibody (anti-PCSK9) | Small interfering RNA (siRNA) |
| Dosing frequency (per label) | Every 2 weeks or monthly | Every 2 weeks | Twice yearly after initial doses |
| LDL-C lowering reported in the 2026 guideline | 45%–84% (class range for PCSK9 antibodies) | 45%–84% (class range for PCSK9 antibodies) | Reported separately by the manufacturer; see prescribing information |
| Cardiovascular outcomes trial evidence (as cited) | FOURIER (NEJM 2017); VESALIUS-CV (NEJM 2025) | ODYSSEY Outcomes (NEJM 2018) | Outcomes trials (ORION-4, VICTORION-2P) in progress per section 3.3 |
| Where it is named in the 2026 guideline | As a PCSK9 antibody add-on option | As a PCSK9 antibody add-on option | As a non-statin, non-antibody LDL-C-lowering option |
Readers can review the underlying evidence in FOURIER, ODYSSEY Outcomes and ORION-10, and the prescribing information for evolocumab and inclisiran.
7. Where the Evidence Is Still Evolving
Reading guideline and trial summaries responsibly means noting the open questions the sources themselves raise:
- Inclisiran outcomes: as described in section 3.3, outcomes trials are pending.
- Guideline timing: the guideline authors acknowledged that VESALIUS-CV results emerged after the guideline was developed and should inform future updates.
- Cost-effectiveness and age of treatment: the JAMA editorial accompanying the VESALIUS-CV diabetes analysis raised these as unresolved questions.
- Population differences: the VESALIUS-CV diabetes subgroup was reported as 93% White. How these results translate to South Asian populations is a question for clinicians and researchers; this article does not draw that conclusion.
- Mortality endpoints: described as hypothesis-generating in the main trial.
8. A US Guideline Read in an Indian Context
The 2026 ACC/AHA guideline is a US document. Indian clinicians also draw on the ESC/EAS dyslipidaemia guidance and on guidance from Indian professional societies; we have not reviewed Indian society guidance for this article and make no statement about how it compares. Likewise, the approved indications for evolocumab, alirocumab and inclisiran can differ between the US FDA label and the label approved by India’s Central Drugs Standard Control Organisation (CDSCO). Any reader looking at a specific product should consult the approved Indian prescribing information and their treating physician.
9. Presentations, Storage and Handling — A Distributor’s Perspective
For institutional pharmacies, supply-chain handling is a practical consideration for injectable biologics and RNA therapies. Storage conditions differ between products and between presentations, so the manufacturer’s pack insert is the reference for each batch. Our product pages summarise the labelled presentations:
| Product | Presentations listed on our product page | Handling note |
|---|---|---|
| Repatha (Evolocumab) | 140 mg/mL pre-filled syringe; 140 mg/mL SureClick autoinjector; 420 mg/3.5 mL monthly system | Refrigerated product; follow the pack insert for room-temperature allowances |
| Praluent (Alirocumab) | 75 mg/mL and 150 mg/mL pre-filled pen or syringe | Refrigerated product; follow the pack insert |
| Sybrava (Inclisiran) | 284 mg/1.5 mL single-dose pre-filled syringe | Follow the pack insert for storage temperature and permitted excursions |
As a licensed pharmaceutical distributor in Delhi, A.K. Pharma stores and dispatches these medicines under manufacturer-recommended conditions, with batch and invoice documentation provided with each order.
10. Sourcing PCSK9-Pathway Medicines in India
A.K. Pharma is a licensed medicine distributor in Delhi supplying Repatha (evolocumab), Praluent (alirocumab) and Sybrava (inclisiran) to hospitals, institutional pharmacies and retail pharmacy partners across India.
10.1 What A.K. Pharma Provides — and What It Does Not
- We provide genuine, properly stored and documented stock of these medicines, with batch traceability and invoicing for institutional buyers.
- We do not prescribe, recommend a dosage, or advise which of these medicines is right for a patient — that decision is between the patient and their treating physician.
- We do not rank these medicines against one another; the comparison in Section 6 is descriptive, drawn from manufacturer and trial-reported information, not a recommendation.
- For supply enquiries, institutional pharmacies and hospitals can reach us at 011 4172 6999 or on WhatsApp at +91 9810034827.
11. Related Cardiology and Cardiometabolic Medicines at A.K. Pharma
- Repatha (Evolocumab) — product page
- Praluent (Alirocumab) — product page
- Sybrava (Inclisiran) — product page
- Vymada — product page
- Browse all Heart and Cardiology medicines
- Related reading: our earlier article on GLP-1 medicines and cardiometabolic health
- Browse our full medicine catalogue
- About A.K. Pharma
What is the 2026 ACC/AHA dyslipidemia guideline?
It is a US guideline published on 13 March 2026 that replaces the 2018 blood cholesterol guideline. According to the ACC summary, it covers cholesterol, triglycerides and lipoprotein(a), reintroduces LDL-C goals, and recommends the PREVENT equations for risk estimation.
What is VESALIUS-CV?
VESALIUS-CV is a randomised trial of evolocumab versus placebo in 12,257 high-risk adults without a prior heart attack or stroke. As reported by TCTMD and published in the New England Journal of Medicine, evolocumab was associated with a 25% relative reduction in the first primary endpoint (HR 0.75) over a median 4.6 years.
Does the guideline name specific PCSK9 medicines?
Yes. The guideline text names evolocumab and alirocumab (PCSK9 monoclonal antibodies) and inclisiran (an siRNA) as options at various classes of recommendation, depending on the clinical scenario. The specific scenario, and whether any of these medicines applies to a particular patient, is a decision for the treating physician.
Does the guideline rank Repatha, Praluent and Sybrava against each other?
The guideline does not present a product-by-product ranking. It describes antibodies and inclisiran in different recommendation contexts, and notes that inclisiran’s outcomes data are pending. A.K. Pharma does not rank or recommend any medicine.
Are the cardiovascular outcomes of inclisiran established?
According to the 2026 guideline and the ACC summary, outcomes data for inclisiran are still pending from trials including ORION-4 and VICTORION-2 PREVENT. Its LDL-C-lowering effect is documented in the ORION trial programme, for example ORION-10.
Do these US findings apply directly to patients in India?
That is a question for treating physicians and Indian clinical guidance. The guideline and trials cited here were developed and conducted largely in other populations, and approved indications can differ between countries. Please consult the approved Indian prescribing information and a qualified doctor.
Is A.K. Pharma giving medical advice in this article?
No. A.K. Pharma is a medicine distributor, not a healthcare provider. This article reports published guidelines and trials for educational purposes. It does not recommend any medicine, dose or treatment for any individual.
Are Repatha, Praluent and Sybrava available in India through A.K. Pharma?
A.K. Pharma supplies Repatha, Praluent and Sybrava to hospitals, cardiology centres and pharmacies across India against valid prescriptions. Availability varies; contact us for current stock.
What is the price of these medicines in India?
Pricing varies by presentation and order volume. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and institutional supply rates.
Disclaimer
A.K. Pharma is a licensed medicine distributor and pharmaceutical distributor in Delhi, not a healthcare provider. We do not diagnose, treat, or prescribe, and nothing in this article is medical advice.
This article is an informational summary of publicly reported guideline updates and clinical trial data (ACC/AHA, ESC Congress 2026, VESALIUS-CV). It reports what guideline authors, investigators, and news coverage have stated; it does not independently verify clinical claims and does not endorse any specific treatment pathway.
Treatment decisions rest solely with the patient and their treating physician, who can weigh the patient’s full medical history, current guidelines, and the approved Indian prescribing information for any medicine named here.
Information is current as of the publication date and may be superseded by later guidance. All product and trial names are trademarks of their respective owners; mention here does not imply endorsement by A.K. Pharma.
About A.K. Pharma — Medicine Distributor in Delhi
A.K. Pharma is a licensed medicine distributor in Delhi, supplying genuine pharmaceutical products — including cardiology, oncology and specialty biologics — to hospitals, institutional pharmacies and retail partners across India. As a pharmaceutical distributor in Delhi, we focus on reliable supply, proper cold-chain handling and documented, traceable stock; we are not a healthcare provider and do not offer medical advice.
Address: E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 · Phone: 011 4172 6999 · WhatsApp: +91 9810034827 · akpharma.in
